|
Neihu, Taiwan (February 05, 2020)
Abnova announced today to speed up Wuhan 2019-nCoV rapid test, therapeutic antibody, and vaccine development. For the rapid test development, Abnova has signed an agreement with Cellspect® Japan to integrate Abnova’s DNAx™ Immune antibody with Cellspect® lateral flow system MSA™ for rapid testing of 2019-nCoV virus. The MSA™ has a proven track record and deployment in Japan as an cost-effective, point-of-care (POC) device for quantification of human samples. The lateral flow testing format is also current industry standard for the POC testing of influenza virus.
Abnova is also speeding up therapeutic antibody development by identifying the receptor binding domain (RBD) of the 2019-nCov virus which binds to the human receptor protein. From the 1/11/2020 published sequence, Wuhan 2019-nCov has similar spike S protein homology to the previous better studied SARS coronavirus S protein. Using DNAx™ Immune technology, Abnova has immunized several crucial DNA epitopes responsible for S protein binding to the human receptor protein. The generated monoclonal antibody will be the basis of humanized therapeutic antibody against 2019-nCoV.
Traditional vaccine development based on attenuated virus take 3-5 years. This is not an acceptable time frame for the Wuhan 2019-nCoV virus outbreak. In contract, the US government and Moderna®, US biotech company, aim to shorten the vaccine development time to 1 1/2 years. Moderna® uses a mRNA vaccine instead of attenuated virus vaccine to generate the protective antibody response. Abnova is contributing to this effort by identifying the crucial 2019-nCoV RNA sequence which is more likely to generate protective antibody based on multitude of immunizations and response from the DNA™ platform. |
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)